CRISPR Therapeutics (CRSP) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tarsus Pharmaceuticals (TARS) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 7.6% versus a loss of 25.9%. Over five years, TARS leads with a +158.1% price change compared with -46.0% for CRSP. CRISPR Therapeutics is the larger company by market cap ($4.88 billion vs $3.38 billion), about 1.4 times the size, while Tarsus Pharmaceuticals is growing revenue faster (+146.7% vs -90.6%).
Tarsus Pharmaceuticals converts more of its revenue into profit, with a net margin of -14.7% versus -16569.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRSP | TARS |
|---|---|---|
| Share price | $50.44 | $72.22 |
| Market cap | $4.88B | $3.38B |
| 1-day change | -3.65% | -1.89% |
| YTD return | -0.17% | -10.10% |
| 1-year return | -25.87% | +7.59% |
| 5-year return | -46.03% | +158.10% |
| EPS (TTM) | $-4.74 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.51M | $451.36M |
| Revenue growth (YoY) | -90.59% | +146.71% |
| Net income (latest FY) | $-581.60M | $-66.42M |
| Operating margin | -18933.65% | -15.72% |
| Net margin | -16569.77% | -14.72% |
| 52-week high | $78.38 | $91.53 |
| 52-week low | $44.12 | $53.89 |
| Distance from 52-week high | -35.65% | -21.10% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +73.59% | +37.77% |
| Average volume | 1.59M | 894.35K |
| Shares outstanding | 96.69M | 46.79M |
| Employees | — | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARS has outperformed CRSP by 33.5 percentage points over the past year.
- Tarsus Pharmaceuticals is more profitable, keeping -14.7 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
- Tarsus Pharmaceuticals grew revenue faster in its latest fiscal year (+146.71% vs -90.59%).
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
CRSP vs TARS FAQ
Which is bigger, CRISPR Therapeutics or Tarsus Pharmaceuticals?
CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $4.88B compared with $3.38B for Tarsus Pharmaceuticals (TARS).
Which stock has performed better over the past year, CRSP or TARS?
TARS returned +7.59% over the past 12 months, compared with -25.87% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are CRISPR Therapeutics and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.